AU2009241645B2 - Products and methods for stimulating an immune response - Google Patents

Products and methods for stimulating an immune response Download PDF

Info

Publication number
AU2009241645B2
AU2009241645B2 AU2009241645A AU2009241645A AU2009241645B2 AU 2009241645 B2 AU2009241645 B2 AU 2009241645B2 AU 2009241645 A AU2009241645 A AU 2009241645A AU 2009241645 A AU2009241645 A AU 2009241645A AU 2009241645 B2 AU2009241645 B2 AU 2009241645B2
Authority
AU
Australia
Prior art keywords
antigen
cells
cell
hel
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009241645A
Other languages
English (en)
Other versions
AU2009241645A1 (en
Inventor
Patricia Barral
Facundo Batista
Vincenzo Cerundolo
Julia Eckl-Dorna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blink Therapeutics Ltd
Original Assignee
University of Oxford
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford, Cancer Research Technology Ltd filed Critical University of Oxford
Publication of AU2009241645A1 publication Critical patent/AU2009241645A1/en
Assigned to BLINK THERAPEUTICS LIMITED reassignment BLINK THERAPEUTICS LIMITED Request for Assignment Assignors: CANCER RESEARCH TECHNOLOGY LIMITED, THE CHANCELLOR, MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD
Application granted granted Critical
Publication of AU2009241645B2 publication Critical patent/AU2009241645B2/en
Priority to AU2014250631A priority Critical patent/AU2014250631B2/en
Priority to AU2014250632A priority patent/AU2014250632B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009241645A 2008-05-02 2009-05-05 Products and methods for stimulating an immune response Ceased AU2009241645B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2014250631A AU2014250631B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response
AU2014250632A AU2014250632B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02
US61/049,814 2008-05-02
PCT/GB2009/001111 WO2009133378A2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2014250632A Division AU2014250632B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response
AU2014250631A Division AU2014250631B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response

Publications (2)

Publication Number Publication Date
AU2009241645A1 AU2009241645A1 (en) 2009-11-05
AU2009241645B2 true AU2009241645B2 (en) 2014-07-17

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009241645A Ceased AU2009241645B2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Country Status (8)

Country Link
US (1) US20110280930A1 (enExample)
EP (3) EP2711021B1 (enExample)
JP (3) JP5721620B2 (enExample)
CN (1) CN102170903B (enExample)
AU (1) AU2009241645B2 (enExample)
CA (1) CA2723226A1 (enExample)
ES (1) ES2570973T3 (enExample)
WO (1) WO2009133378A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723226A1 (en) * 2008-05-02 2009-05-11 Cancer Research Technology Ltd Products and methods for stimulating an immune response
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP6100762B2 (ja) 2011-06-02 2017-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 膜で被包されたナノ粒子および使用方法
TW201442739A (zh) * 2013-02-27 2014-11-16 Riken 過敏疾病治療藥
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) * 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
CN106163504B (zh) 2014-03-20 2021-02-09 加利福尼亚大学董事会 水凝胶毒素-吸收或结合纳米颗粒
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
JP7094533B2 (ja) * 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
US10610493B2 (en) 2015-04-29 2020-04-07 The Regents Of The University Of California Detoxification using nanoparticles
CN107708740A (zh) * 2015-06-10 2018-02-16 萨尔布吕肯大学 用于治疗b细胞恶性肿瘤的手段和方法
EP3411475B1 (en) 2016-02-06 2025-08-27 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017211316A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting the presence of mycobacterial material in a sample using at least two antigens
NL2017204B1 (en) 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
CN115537372A (zh) 2016-07-13 2022-12-30 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
EP3493842A4 (en) 2016-08-02 2020-07-29 President and Fellows of Harvard College BIOMATERIALS TO MODULATE IMMUNE RESPONSES
WO2018035303A1 (en) * 2016-08-17 2018-02-22 Orbis Health Solutions Llc Tumor-targeting bead vectors and methods of using the same
WO2019032862A1 (en) * 2017-08-10 2019-02-14 Dana-Farber Cancer Institute, Inc. CELLS EXPRESSING LMP1 AND METHODS OF USE
NL2021443B1 (en) 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092607A1 (en) * 2005-03-02 2006-09-08 The Secretary Of State For Defence Pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
ES2092560T5 (es) 1989-12-22 2004-09-16 Mikrogen Molekularbiologische Entwicklungs-Gmbh Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3215109B2 (ja) 1991-02-15 2001-10-02 ユーエイビー リサーチ ファウンデーション 肺炎球菌タンパクの構造遺伝子
EP0598816B1 (en) 1991-08-15 1999-06-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
AU711183B2 (en) 1994-08-19 1999-10-07 Biotransplant Incorporated Genetically engineered swine cells
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
US20070104726A1 (en) * 2002-08-14 2007-05-10 Avidis Sa Multimeric complexes of antigens and adjuvants
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
EP1694301A4 (en) * 2003-12-02 2009-11-18 Cytimmune Sciences Inc METHOD AND COMPOSITIONS FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
WO2006002642A2 (en) * 2004-07-07 2006-01-12 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
JP5117191B2 (ja) * 2004-10-01 2013-01-09 ミダテック リミテッド 抗原及びアジュバントを含むナノ粒子、並びに免疫原性構造
WO2007050668A1 (en) 2005-10-25 2007-05-03 Ludwig Institute For Cancer Research Analogs of alpha galactosylceramide and uses thereof
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
CA2723226A1 (en) * 2008-05-02 2009-05-11 Cancer Research Technology Ltd Products and methods for stimulating an immune response
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092607A1 (en) * 2005-03-02 2006-09-08 The Secretary Of State For Defence Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIDARD, L. et al., ' Analysis of MHC Class II Presentation of Particulate Antigens by B Lymphocytes', The Journal of Immunology, 1996, Vol 156, pages 2809-2818 *

Also Published As

Publication number Publication date
CN102170903A (zh) 2011-08-31
EP2711021A1 (en) 2014-03-26
US20110280930A1 (en) 2011-11-17
EP2711020A1 (en) 2014-03-26
WO2009133378A3 (en) 2009-12-23
JP5853068B2 (ja) 2016-02-09
JP2015038066A (ja) 2015-02-26
ES2570973T3 (es) 2016-05-23
EP2711020B1 (en) 2016-08-10
EP2288381A2 (en) 2011-03-02
WO2009133378A2 (en) 2009-11-05
HK1190942A1 (en) 2014-07-18
JP2015028023A (ja) 2015-02-12
AU2009241645A1 (en) 2009-11-05
CA2723226A1 (en) 2009-05-11
JP5721620B2 (ja) 2015-05-20
EP2711021B1 (en) 2016-03-09
JP2011519847A (ja) 2011-07-14
HK1191548A1 (en) 2014-08-01
HK1161542A1 (zh) 2012-07-27
CN102170903B (zh) 2016-04-06

Similar Documents

Publication Publication Date Title
AU2009241645B2 (en) Products and methods for stimulating an immune response
Pedersen et al. Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses
US12246097B2 (en) Nanoparticle vaccine adjuvant and methods of use thereof
US20110293658A1 (en) Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
US20120328660A1 (en) Immunogenic compositions useful in provoking an integrated response to tumor antigens
EP1487477A2 (en) Methods of using flt3-ligand in immunization protocols
AU2014250631B2 (en) Products and methods for stimulating an immune response
EP2651435B1 (en) Method for suppressing an immune response
HK1190942B (en) Products and methods for stimulating an immune response
HK1191548B (en) Products and methods for stimulating an immune response
AU2016240410A1 (en) Pain treatment
HK1161542B (en) Products and methods for stimulating an immune response
US20210299252A1 (en) Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination
WO2023114570A1 (en) Compositions and methods for long-lasting germinal center responses to a priming immunization

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BLINK THERAPEUTICS LIMITED

Free format text: FORMER APPLICANT(S): CANCER RESEARCH TECHNOLOGY LIMITED; THE CHANCELLOR, MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired